RBC Capital Maintains Outperform on Knight Therapeutics, Raises Price Target to C$13

Benzinga · 1d ago
RBC Capital analyst Douglas Miehm maintains Knight Therapeutics (TSX:GUD) with a Outperform and raises the price target from C$11 to C$13.